Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Increased to Sell at StockNews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research report issued on Wednesday. Several other equities research analysts have also issued reports on LXRX. SVB Leerink began coverage on shares of Lexicon Pharmaceuticals in a report on Tuesday. They set an “outperform” rating […]

Leave a Reply

Your email address will not be published.

Previous post Matson (NYSE:MATX) Rating Increased to Buy at StockNews.com
Next post Analysts Set Plains All American Pipeline, L.P. (NYSE:PAA) Price Target at $18.96